IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Average Recommendation of “Moderate Buy” by Brokerages

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has been given a consensus rating of “Moderate Buy” by the ten analysts that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $751.00.

IDXX has been the topic of a number of research reports. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $552.46 on Wednesday. The business’s 50-day moving average price is $555.50 and its 200-day moving average price is $597.62. IDEXX Laboratories has a 12 month low of $518.55 and a 12 month high of $769.98. The firm has a market capitalization of $43.58 billion, a price-to-earnings ratio of 40.68, a PEG ratio of 3.08 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts forecast that IDEXX Laboratories will post 14.68 EPS for the current year.

Institutional Investors Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC lifted its stake in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after acquiring an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $265,000. Jump Financial LLC increased its position in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after purchasing an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $164,000. Finally, Sei Investments Co. raised its holdings in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after purchasing an additional 82,755 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.